|
|
 |
|
Viewing report
|
|
|
|
Drug Targets for Breast Cancer
Informa Healthcare, Jan 2006, Pages: 170
Breast cancer is a complex heterogeneous disease characterised by uncontrolled growth and spread of abnormal cells. It is also very prevalent, with reports from the World Health Organization estimating that more than 1.2 million people will be diagnosed with breast cancer in 2005, worldwide. In the United States, breast cancer is the second most common cancer in women (following skin cancer) with 212,930 new cases estimated for 2004 and an associated 40,840 deaths. In Europe, approximately 200,000 women are diagnosed with breast cancer each year (41,000 in the UK). Consequently, breast cancer is a high-priority research area and is recognized as one of the most aggressively pursued diseases in the history of medicine.
Encouragingly, cancer drug therapy is in a time of major transition. This time has been described by Bristol Myers Squibb (New York, NY), as a “golden era,” where decades of cancer research are now being translated into development of next generation therapeutics. Current pharmaceutical pipelines are testimony to the intensity of breast cancer drug development with at least 50 investigational drugs and drug combinations in clinical development.
Breast cancer treatment generally comprises of combinations that include surgery, radiotherapy, hormonal therapy, and chemotherapy. Clinical pipelines now reflect the emergence of two additional new therapy classes, namely, “innovative therapy” and “immunotherapy”. Current treatment is dominated by hormone or endocrine therapy as approximately 70% of breast cancers are hormone-responsive. But early treatments from the new classes are now reaching the market and are set to revolutionise therapy.
This report features:
- An overview of recent developments in breast cancer research
- Clearly explains the new approaches to tackling this disease
- Profiles the new treatments coming to market
- Takes an in-depth look at the portfolios of the major developers in this market
This report will allow you to:
- Understand recent developments in breast cancer research and how they are set to revolutionise the market
- Track the development activities of your competitors
- Identify the potential of new treatments and treatment approaches for breast cancer
Customers who bought this item also bought
Drug Delivery in Cancer - Technologies, Markets and Companies
Future Oncology
Breast Cancer Vaccines and Therapeutic Antibodies: Pipeline - 2011
Breast Cancer Therapeutics - Global Strategic Business Report
U.S. Breast Cancer Therapeutics Markets
Lung Cancer Vaccines and Therapeutic Antibodies: Pipeline, Strategies and Clinical
Cancer Therapeutics - Market Insight and R&D Pipeline Analysis
Challenges and Opportunities in Developing Chemopreventive Agents
Royalty Rates for Pharmaceuticals & Biotechnology, 7th Edition
Breast Cancer Drug Discoveries: What the Future Holds
|
|
|
|
